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ABSTRACT 
As practice effects are common in neuropsychological assessment, this study analyzed 
their utility to identify individuals with amnestic Mild Cognitive Impairment (aMCI) at 
the greatest risk for Alzheimer’s disease (AD-risk), and compared practice effects with 
APOE and brain metabolism biomarkers. We regressed Auditory Verbal Learning Test 
delayed recall (AVLT-DR) at six months on baseline AVLT-DR scores in 394 individuals 
with normal cognition (NC) from the ADNI database, and dichotomized 816 individuals 
with aMCI as showing (PE+) or not showing practice effects (PE-) when the discrepancy 
between observed and predicted scores was found in less than 10%, 7% and 5% of NC. 
Cox regressions analyzed the AD-risk at 6 years. More than 60% of aMCI were PE+. 
Controlling for age, sex, education, and baseline MMSE and AVLT-DR scores, the AD-
risk was associated with PE- (HR=1.93), lower brain metabolism (HR=0.95) and APOE 
genotype (HR=1.92), with narrower risk estimates for PE-. The lack of practice effects 
during a six months period might be as precise as biomarkers for predicting the 6-year 
AD-risk.  
 
Keywords: Alzheimer’s disease; Cognitive Impairment; Dementia; Mild Cognitive 
Impairment; Neurodegenerative; Practice effects 
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1. INTRODUCTION 
The annual risk estimates of progression from aMCI to AD (AD-risk) is around 8% in 
specialist clinical settings and 7% in community studies (Mitchell and Shiri-Feshki, 
2009), which implies that a majority of individuals with aMCI will remain stable or even 
revert to normal. The clinical implication of this is that repeated cognitive testing is 
essential to identify those individuals with progressing cognitive decline, and hence at 
the greatest AD-risk (Albert et al., 2011).  
Repeated cognitive testing can lead to incorrect conclusions if an individual’s 
performance is compared against the same normative data on two occasions, because 
an increase in performance is expected for a number of cognitive tests due to the 
exposure to the same test in a previous occasion. This phenomenon, known as practice 
effects (Duff, 2012), has been documented in several populations including MCI 
(Calamia et al., 2012). Practice effects on memory tests have been reported in 
individuals with aMCI within the same session (Duff et al., 2012) and over periods of 
one week (Duff et al., 2017a), eighteen months (Campos-Magdaleno et al., 2017) and 
even 5 years (Gavett et al., 2016), and have proven useful to identify individuals with 
aMCI who will show larger cognitive decline after one year follow-up (Duff et al., 
2011). However, some researchers have reported no practice effects in individuals 
with aMCI over different periods (Darby et al., 2002; Schrijnemaekers et al., 2006), so 
their utility remains controversial. 
Practice effects have been associated with APOE ε4 genotype (Machulda et al., 2013; 
Zehnder et al., 2009) and with brain metabolism, which in turn have been associated 
with the AD-risk. It is known that APOE ε4 carriers, mostly those carrying two copies of 
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the allele, have an increased AD-risk compared to APOE ε4 non-carriers and carriers of 
APOE ε2 and ε3 alleles (Elias-Sonnenschein et al., 2011; Qian et al., 2017; Yu et al., 
2014). In one study on practice effects (Machulda et al., 2013), APOE carriers failed to 
sustain their initial practice effects over one year, with a level of performance similar 
to baseline after approximately 6 years of follow-up. Regarding brain metabolism, 
although data on the accuracy of FDG-PET are highly variable (Smailagic et al., 2015), 
FDG-PET has been suggested as a more sensitive tool than cognitive scores for 
predicting AD in aMCI (Herholz et al., 2011). FDG-PET has been associated with 
practice effects on tests of visual and verbal memory, with more brain 
hypometabolism being associated with worse cognitive performance and lower 
practice effects (Duff et al., 2015, 2014). However, the associations between practice 
effects and the AD-risk, and also the differential predictive value of AD for practice 
effects, APOE genotype and brain metabolism was not analyzed in either of these 
previous studies. 
In the present study, we aimed to analyze whether practice effects in aMCI over two 
successive assessments can help to identify individuals at the greatest AD-risk, and also 
to compare the predictive value of practice effects with APOE genotype and brain 
metabolism measured with FDG-PET. We expected that individuals with aMCI who did 
not show practice effects would have the greatest AD-risk compared to those with 
aMCI who did show practice effects (Duff et al., 2011; Hassenstab et al., 2015). Due to 
the lack of previous comparisons among practice effects, APOE and FDG-PET, we could 
not make a priori hypotheses about a superior predictive value for any of the variables 
analyzed.  
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2. METHODS 
2.1. Sample data 
Data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database 
(adni.loni.usc.edu) were used in this study. The ADNI was launched in 2003 as a public-
private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary 
goal of the ADNI has been to test whether serial magnetic resonance imaging (MRI), 
positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of MCI 
and early AD. For up-to-date information, see www.adni-info.org. 
The Normal cognition group (NC) included 394 participants (48.2% females) aged 56 to 
89 years with no depression or metabolic diseases, no cognitive complaints, a Clinical 
Dementia Rating scale (CDR) score = 0, Mini-Mental State Examination (MMSE) score 
equal or higher than 24, normal education-corrected Logical Memory (LM) delayed 
recall scores, and no significant impairments in activities of daily living. In the aMCI 
group (Petersen et al., 1999), 816 participants (40.8% females) aged 55 to 91 years 
with no metabolic diseases had subjective cognitive complaints, MMSE score ≥24, CDR 
score = 0.5 (mandatory memory box score ≥0.5), abnormal education-corrected LM 
delayed recall scores, general cognition and functional performance largely intact, and 
did not meet criteria for dementia. Five participants (0.6%) had mild depressive 
symptoms. All participants underwent physical and neurological examinations, 
screening laboratory tests, and provided blood samples for DNA and APOE testing. The 
ethical committee at each participating site approved the project, and all ADNI 
participants provided written consent before enrollment at each site. 
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2.2. Procedure 
Data from 394 NC participants free of any type of dementia during a 6-year follow-up 
period (range: 6-72 months) were used to regress Auditory Verbal Learning Test (AVLT) 
delayed recall scores at six months on baseline RAVLT delayed recall scores. Then, 
baseline AVLT scores, the intercept, beta coefficient and standard error of the 
regression equation were used to predict six-months AVLT delayed recall scores in 
each aMCI participant. Predicted retest scores were subtracted from observed retest 
scores, and this discrepancy was divided by the standard error of a predicted score for 
a new case [(Tobserved – Tpredicted)/Sn+1] according to Crawford and Garthwaite (2007). 
The standardized discrepancy was compared against a t distribution with n-2 degrees 
of freedom (Crawford and Garthwaite, 2007), which is preferred over a normal 
distribution because it treats the sample used to build the regression equation as a 
sample and not as a population, and it has a lower rate of type I error compared to a z 
distribution (Crawford and Garthwaite, 2005). However, as the sample used to build 
the regression equation was large, p-values associated with discrepancies were similar 
to those obtained using a normal distribution (data not shown).  
The p-value associated to the tn-2 statistic can be interpreted as the percentage of 
individuals from the sample used to build the regression equation showing a similar or 
more extreme discrepancy (Crawford and Garthwaite, 2007), which could be 
interpreted as a percentile from a distribution of discrepancies. Based on statistical 
cut-off points used in the literature to define objective cognitive impairment, we used 
the bottom 10%, 7% and 5% of the NC group, which correspond to z-scores of 
approximately -1.28, -1.5 and -1.64 respectively for a one-sided test. Participants 
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showing a negative discrepancy at or below any of the cut-points were labeled as not 
showing practice effects (PE-), and as showing practice effects (PE+) if the discrepancy 
was above the cut-points or positive.   
 
2.3. FDG-PET measures 
For information about neuroimaging data acquisition see 
http://adni.loni.usc.edu/data-samples/pet/. Participants glucose levels were measured 
two hours after the last ingestion, and FDG-PET scans performed 30 minutes after 
intravenous administration of [
18
F]-FDG if blood glucose level was <180 mg/dL (9.9 
mmol/L). The variable FDG from the ADNIMERGE file was analyzed, which indicates the 
baseline average FDG uptake of angular, temporal and posterior cingulate gyri. 
Individuals with AD have lower values than MCI and NC, so higher values of FDG-PET 
indicate higher cerebral metabolism (Landau et al., 2011). To facilitate interpretation 
of the results from a regression model (see Section 2.5), FDG-PET values were 
multiplied by 100 for values to show the difference in the AD-risk for one unit increase 
in FDG-PET metabolism. Using this scale is also easier to interpret than using 
exponentiated values. The aMCI sample decreased to 627 participants due to missing 
FDG-PET values. 
 
2.4. Outcome 
We analyzed the difference in the AD-risk (McKhann et al., 2011, 1984) during a 6 year 
follow-up period. 
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2.5. Statistical analysis 
Raw baseline and 6-months AVLT-DR scores were analyzed separately for NC and MCI 
groups with paired t-tests and Pearson’s correlation coefficients. Demographic and 
continuous variables were compared between groups with ANOVAs, which provide 
eta-squared measures as effect size. Values of 0.01 are considered a small effect, 
values of 0.06 are considered a medium effect, and values of 0.14 are considered a 
large effect (Richardson, 2011). Sex ratio was compared with a chi-square test.  
The AD-risk was compared with hazard ratios (HR) from a multivariable backward 
stepwise Cox proportional regression model. The first step included age, sex and 
education as demographic variables. The second step included PE+ and PE- groups, 
with baseline AVLT and MMSE scores as covariates. Including baseline AVLT scores 
allowed us controlling whether the AD-risk for PE- and PE+ groups was above and 
beyond baseline AVLT-DR scores, as in previous research (Duff et al., 2017b, 2015, 
2011; Gavett et al., 2016; Hassenstab et al., 2015). The third step added APOE and 
FDG-PET biomarkers. 
We performed a separate Cox regression model for each cut-off points used to define 
PE-. We did not to use a model with all the three cut-off points because of a high 
collinearity, with variance inflation factors being 5.20 to 10.92. Lastly, the risk of having 
at least one copy of the APOE ε4 allele was compared between PE+ and PE- groups 
using odds ratios (OR). All statistical analyses were performed using SPSS v.23, with 
alfa level set at 0.05. 
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2.6. Analyses with missing data 
To check if our results would replicate in a sample without missing values, we used the 
Missing Values Analysis (MVA) to highlight patterns of missing values and also to 
replace them in the dataset (Tabachnick and Fidell, 2013). First, we analyzed whether 
missingness in FDG-PET measures was related to each of the variables introduced in 
the regressions analyses plus progression status using the Separate Variance t-test. 
Whether the data were missed at random was analyzed with the Little’s Missing 
Completely at Random test (MCAR). We then imputed FDG-PET values using MVA 
regression to estimating missing values. As estimates from regression can only be used 
if estimated values fall within the range of values for complete cases (Tabachnick and 
Fidell, 2013), we analyzed with an independent samples t-test the differences in the 
distribution of scores between cases with complete values and cases with estimated 
values. Lastly, we repeated the Cox proportional hazard regression for the 5% cut-off.  
 
2.7. Comparison of the risk of AD according to clinical profile 
Using the dataset with complete and estimated values, we categorized participants 
into one of four groups according to the clinical profile: 1) participants showing no 
practice effects, 2) participants having at least one APOE allele, 3) participants with 
both conditions, and 4) participants showing practice effects and not having APOE 
alleles. This latter group was used as the reference group for comparisons. The AD-risk 
was compared among groups using a Cox regression with age, sex, education, and 
MMSE and AVLT baseline scores.   
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3. RESULTS 
NC and MCI groups differed on age, level of education, sex ratio, MMSE scores, 
baseline AVLT scores, 6-months AVLT scores and brain metabolism (Table 1). 
Differences were negligible for education, small for age and FDG-PET values, medium 
for baseline and 6-months AVLT scores, and large for MMSE scores. Compared to MCI, 
NC were slightly older, were more educated, had higher MMSE scores, higher baseline 
and 6-months AVLT-DR scores, more brain hypermetabolism, and more female 
participants. Participants with MCI had a statistically significantly higher probability of 
having at least one copy of the APOE ε4 allele. Individuals in the aMCI group were 
followed for an average period of 38.94 months (SD=21.59, range 6 to 72 months). 
NC test-retest AVLT scores were similar (mean difference (MD) = 0.16, 95%CI = -0.09, 
0.42, t(393) = 1.28, p = .202), with both scores being statistically significantly correlated 
(r(394) = 0.44, p < .001). Test scores predicted retest scores (Intercept=6.92, standard 
error = 2.18, β=0.45, p < .001). In the MCI group, retest scores were statistically 
significantly lower than test scores (MD = 0.43, 95%CI = 0.22, 0.64, t(815) = 4.07, p < 
.001), with both scores being statistically significantly correlated (r(816) = 0.64, p < 
.001). The percentage of participants obtaining a higher retest AVLT-DR score were 
32.5% and 33.8% for NC and aMCI groups respectively (χ2(1, N = 1,210) = 0.21, p = 
.644).  
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3.1. aMCI groups based on practice effects 
The number of PE- were smaller as the cut-off point used to define impairment was 
more restrictive, from 257 (31.5%) for a 10% cut-off point to 221 (27.1%) for a 7% cut-
off point and 196 (24%) for a 5% cut-off point. Participants in the PE- group were more 
likely to have at least one copy of the APOE ε4 allele using a 10% cut-off (OR = 1.69, 
95%CI = 1.26, 2.29, p = .001), a 7% cut-off (OR = 1.86, 95%CI = 1.35, 2.55, p < .001) and 
a 5% cut-off (OR = 1.95, 95%CI = 1.40, 2.72, p < .001) than participants in the PE+ 
group. One hundred and seventy-five (21.4%) individuals in the aMCI sample 
progressed to AD. The percentage of progressors to AD in the PE-/PE+ groups was 
35/15.2%, 37.6/15.5% and 39.3/15.8% for 10%, 7% and 5% cut-off points respectively.  
 
3.2. Risk of progression to AD 
Results from Cox regressions (table 2) indicated that only age was associated with the 
AD-risk among demographics, irrespective of the cut-off point. When cognitive 
variables were added to the model, lower baseline AVLT and MMSE scores, and PE- 
were associated with an increased AD-risk. When biomarkers were added to the 
model, more hypometabolism from FDG-PET and having at least one APOE e4 allele 
were associated with an increased AD-risk. The model including all the variables 
showed that having two APOE e4 alleles and not showing practice effects were the 
variables with the highest risk estimates, with PE- showing less heterogeneity and 
narrower confidence intervals and APOE becoming non-significant. As results were 
identical for the three cut-off points used to define the no practice effects groups, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
table 2 shows results for the 5% cut-off point as commonly reported when using a z-
score equal or lower than -1.645 (Duff, 2012) for a one-tailed test. 
 
3.3. Analysis of missing FDG-PET values 
Separate Variance t-test showed that FDG-PET missing values were associated with age 
(p = .006), education (p = .022), MMSE (p < .001), baseline AVLT-DR scores (p < .001), 6-
months AVLT scores (p < .001), follow-up (p < .001), and progression to AD (p < .001), 
but not with gender (p = .486) or APOE (p = .661). Participants with missing FDG-PET 
values were slightly older, were less educated, had a slightly lower MMSE and lower 
baseline and 6 months AVLT scores, and were followed for a shorter follow-up period. 
Little’s MCAR test showed that values were not missing completely at random (χ2(6, N 
= 816) = 79518.03, p < .001). Independent samples t-test showed that estimated values 
(M = 123.89, SD = 12.04) fell in the range of values for complete cases (M = 124.43, SD 
= 13.44, t(814) = -0.54, p = .620). Cox proportional hazard regression replicated the 
results of analyses with values for complete cases. Older age (HR = 1.03, p = .016), 
lower MMSE (HR = 0.83, p < .001) and baseline AVLT scores (HR = 0.92, p < .001), 
having at least one ε4 allele, not showing practice effects and having a lower brain 
metabolism were associated with an increased AD-risk. However, although PE- again 
showed the most precise estimate of the AD-risk, the hazard ratio was higher for PE- 
(HR = 1.89, p < .001) than for APOE (HR for 1 ε4 allele = 1.64, p = .004; HR for 2 ε4 
alleles = 1.65, p = .040) and FDG-PET (HR = 0.97, p < .001).  
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3.4. Comparison of the AD-risk according to clinical profile 
Cox proportional hazard regression showed that the AD-risk was higher for those 
showing no practice effects only (HR = 2.49, p = .001), those having at least one APOE4 
allele only (HR = 1.97, p = .002), and those having both conditions (HR = 3.41, p < .001) 
compared to those showing practice effects and with no APOE4 alleles. Figure 1 shows 
how the absolute AD-risk for participants with aMCI over a 6 year follow-up changes 
according to the available information. As shown, if an individual meets standard 
criteria for aMCI at baseline assessment, the expected AD-risk at six years without any 
additional information is 21.4%. If APOE testing is added to the medical record, the AD-
risk increases for individuals with at least one APOE allele, with a risk estimate twice as 
high as that for APOE negative individuals. Adding data on practice effect obtained on 
a follow-up visit six months after baseline assessment again modifies the risk 
estimates. The AD-risk among APOE negative individuals is three times as high for 
individuals not showing practice effects, and is also higher than the risk estimate for 
aMCI at baseline. Among individuals with at least one APOE allele, those not showing 
practice effects have the greatest AD-risk, with a risk estimate twice as high as that for 
aMCI diagnosis at baseline. Interestingly, the AD-risk for APOE negative individuals not 
showing practice effects is higher than the AD-risk for APOE positive individuals 
showing practice effects.  
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4. DISCUSSION 
This study aimed to analyze the value of practice effects on a list learning test between 
two assessments, conducted 6 months apart, for predicting progression from aMCI to 
AD during a 6 years follow-up period. We found that individuals with aMCI who did not 
show practice effects as expected based on a healthy comparison group had a 
significantly higher AD-risk, and also that the risk estimate for practice effects was 
higher than that for FDG-PET data and similar and more precise than that for APOE 
genotype.  
Our results partially agree with previous research analyzing practice effects in aMCI. 
Contrary to what has been previously reported using verbal (Duff et al., 2008) and 
visual memory tests (Duff et al., 2007), we did not find significant improvements on 
AVLT delayed recall scores at retest in the aMCI sample. A possible explanation for this 
discrepancy could be related to the test-retest interval, which is inversely related to 
practice effects (Calamia et al., 2012). Whereas the studies by Duff et al. (2008, 2007) 
analyzed practice effects during 1-week and 2-week period, a 6-month period was 
used in this study. However, factors other than the length of follow-up must be 
considered, as practice effects have been reported for periods of 18 months after 
baseline assessment (Campos-Magdaleno et al., 2017). A possible explanation is that 
the large sample size in this study mitigated statistical characteristics of cognitive 
performance such as regression to the mean, which has also been associated with 
practice effects (Duff, 2012). The most important finding, however, is that more than 
65% of individuals with aMCI showed practice effects when methods other than raw 
scores were used to define practice effects. Despite there being up to a third of 
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individuals with aMCI showing higher retest scores relative to baseline, 25% of the 
aMCI sample did not show significant practice effects. It is thus important to identify 
the frequency of test-retest changes in raw scores to more reliably identify practice 
effects. 
This work used the regression-based reliable change index with that purpose, 
and used a tn-2 distribution to identify the distribution of discrepancies between 
observed and predicted scores. This procedure has been suggested to more reliable 
identify true change compared to a z distribution, specially for small samples 
(Crawford and Garthwaite, 2007). This work is the first that analyzes practice effects 
for three different cut-off points along the distribution of discrepancies, and the one 
reporting that the estimate of the AD-risk in aMCI is similar for the lower 10%, 7% and 
5% distribution of discrepancies between observed and predicted raw scores.  
 The main finding is that cognitive data, assessed through practice effects, were 
at least as useful for predicting AD over 6 years as genetic and biomarker data, results 
that were replicated when FDG-PET missing values were imputed using variables 
associated with missingness. Although practice effects were related to genetic data as 
previously reported (Duff et al., 2017b; Machulda et al., 2013), with the PE- group 
being more likely to have at least one copy of the APOE ε4 allele, the lack of practice 
effects outperformed FDG-PET in the identification of individuals at the greatest AD-
risk, and showed a similar and more precise risk estimate than APOE genotype. This 
results are in line with those reported by Hassenstab et al. (2015), who found that 
APOE was not significant to predict worsening of clinical symptoms of cognitive 
impairment, and cannot support that FDG-PET are more sensitive than cognitive scores 
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for predicting AD in aMCI (Herholz et al., 2011). Duff et al. (2015) suggested that 
practice effects can be a proxy of certain biomarkers, and our data add that practice 
effects and biomarkers might be a useful combination to identify individuals at the 
greatest AD-risk during a 6-year follow-up. However, risk estimates for APOE and FDG-
PET may be biased due to the association of these two variables in the ADNI database 
(Landau et al., 2013). Our results are also in line with the findings reported by 
Machulda et al. (2013), who found that APOE carriers’ performance was similar to 
baseline after an average follow-up period of 6 years. Thus, future works will replicate 
whether practice effects are similar or even superior to genetic and biomarker data for 
predicting progression to AD in different follow-up periods. 
Although promising, these results have some limitations. The ADNI project 
included only one cognitive test to define cognitive impairment in aMCI. Recent 
diagnostic approaches have reported both NC and MCI misdiagnoses when cognitive 
impairment is defined using several tests (Edmonds et al., 2015; Oltra-Cucarella et al., 
2018). Second, to avoid circularity between test-retest regressions and risk analyses, 
we used a simple regression to predict retest AVLT-DR scores using baseline AVLT-DR 
scores without including other covariates. The use of a simple regression could have an 
impact on the discrepancy between observed and predicted scores, with multiple 
regressions providing a larger discrepancy (Duff et al., 2017a). However, the 
calculation of the standard error for a new case after conducting multiple regressions 
is computationally much more complicated than for simple regressions (Crawford et 
al., 2012), so using a simple regression may be more feasible to estimate the AD-risk in 
clinical practice where correlations between predictors are seldom available. The small 
and negligible differences between NC and MCI on age and education suggest that 
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these variables might have a little effect on the prediction of retest scores. Future 
research will clarify whether the use of multiple regressions provides additional 
information for the identification of individuals at an increased AD-risk over simple 
regressions.  
Our results have important clinical implications that must be highlighted. The 
most recent criteria for MCI due to AD include biomarkers to define levels of certainty 
that MCI is a prodromal stage of AD (Albert et al., 2011). Our results show that practice 
effects can provide an estimate of the AD-risk over and above biomarker and genetic 
data, even if raw scores (particularly extreme low scores) increase at the second 
assessment in a proportion of individuals. Our findings could also be useful for 
interpreting the results of clinical trials (Brooks and Loewenstein, 2010), as it has been 
shown that it is important not only to identify changes in raw scores over a 6 months 
period but also to identify whether negative discrepancy between observed and 
expected scores are uncommon in healthy individuals who do not progress to AD. 
Showing a negative discrepancy at the bottom 10% of healthy individuals must warn 
about the increased AD-risk in individuals with aMCI. This would help to reduce the 
possibility that practice effects mask treatment effects (Goldberg et al., 2015), would 
help to identify eligible individuals for intervention trials, and also to interpret the 
presence of increased retest scores in those receiving cognitive or pharmacological 
interventions. 
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Conclusions 
Rather than a source of error, the analysis of practice effects may be a valuable 
tool for the identification of individuals with aMCI at the greatest AD-risk. Practice 
effects on a verbal memory test may identify as accurately as genetic and biomarker 
data individuals with aMCI at the greatest AD-risk in a 6 year follow-up. Our results 
warrant further research with samples diagnosed with MCI using standard criteria, and 
for different test-retest periods and follow-up intervals. 
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FIGURE CAPTIONS 
Figure 1. Estimates of the absolute AD-risk at six years according to clinical profile 
NC: normal cognition. MCI: mild cognitive impairment. APOE+: individuals with one or 
more APOE allele. APOE-: individuals with no APOE allele. PE+: individuals showing 
practice effects on the 6-months Auditory Verbal Learning Test test-retest. PE-: 
individuals not showing practice effects on the 6-months Auditory Verbal Learning Test 
test-retest 
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Table 1. Demographic, cognitive, genetic and biomarker data 
 
NC (n = 394) 
Mean (SD) 
MCI (n = 816) 
Mean (SD) t/χ2 P 
Age 74.83 (5.73) 73.06 (7.47) 4.16 < .001 
Years of education 16.30 (2.73) 15.92 (2.86) 2.32 .026 
Sex (M/F) 204/190 483/333 5.95 .015 
MMSE 29.06 (1.14) 27.56 (1.82) 14.91 < .001 
AVLT baseline 12.82 (2.42) 10.49 (3.48) 11.91 < .001 
AVLT 6-months 12.66 (2.44) 10.06 (3.65) 12.82 < .001 
Ethnicity 
    
Not hispano/latino, n (%) 378 (95.9) 787 (96.4)   
Hispano/latino, n (%) 14 (3.6) 25 (3.1)   
Unknown, n (%) 2 (0.5) 4 (0.5) 0.21 .902 
Married, n (%) 268 (68) 632 (77.5) 19.28 .001 
APOE ε4     
0, n (%) 287 (72.8) 397 (48.7)   
1, n (%) 96 (24.4) 327 (40.1)   
2, n (%) 11 (2.8) 92 (11.3) 68.72 < .001 
FDG-PET 130.70 (11.47) 124.43 (13.44) 6.71 < .001 
NC: normal cognition. MCI: mild cognitive impairment. MMSE: Mini-Mental State Examination. 
AVLT: Auditory Verbal Learning Test. FDG-PET: fluorodeoxyglucose positron emission 
tomography. APOE: apolipoprotein E 
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Table 2. Cox proportional hazard ratios of risk for Alzheimer’s disease 
 Model 1 Model 2 Model 3 
 HR (95%CI) p HR (95%CI) p HR (95%CI) p 
Age 1.06 (1.03, 1.09) .000 1.04 (1.00, 1.07) .025 1.04 (1.00, 1.07) .022 
Education 0.99 (0.92, 1.08) .933     
Sex 0.89 (0.57, 1.39) .623     
MMSE   0.79 (0.70, 0.90) .000 0.85 (0.75, 0.97) .017 
AVLT-DR   0.89 (0.83, 0.95) .000 0.92 (0.86, 0.97) .005 
FDG-PET     0.95 (0.94, 0.97) .000 
1 APOE ε4 allele     1.51 (0.92, 2.47) .105 
2 APOE ε4 alleles     1.92 (0.99, 3.71) .052 
PE tn-2 10% --  1.73 (1.10, 2.72) .017 1.58 (1.00, 2.48) .047 
PE tn-2 7% --  1.94 (1.23, 3.06) .004 1.79 (1.13, 2.81) .012 
PE tn-2 5% --  2.10 (1.33, 3.33) .002 1.93 (1.22, 3.05) .005 
MMSE: Mini-Mental State Examination. AVLT-DR: baseline Auditory Verbal Learning Test delayed recall 
scores. FDG-PET: fluorodeoxyglucose positron emission tomography (N = 815). APOE: apolipoprotein E-4. 
PE tn-2: practice effects using a tn-2 distribution as defined in the text. HR: hazard ratio. CI: confidence 
interval. Separate backward stepwise Cox regressions were performed for PE tn-2 10%, PE tn-2 7% and PE 
tn-2 5% 
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Highlights 
 
 
1. Practice effects can identify individuals at the greatest risk for Alzheimer’s disease 
2. Practice effects might be as useful as APOE or FDG-PET to identify progressors to AD 
3. These results are important for both clinical trials and clinical settings 
4. Whether the same results are replicated in different samples warrants further 
research 
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